Business
Isodiol International Inc. Reports Fiscal Year 2018 Audited Financial Results
Isodiol International Inc. Reports Fiscal Year 2018 Audited Financial Results.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, July 30, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLD) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods, and the manufacturing of pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), reports audited revenues for the Fiscal Year Ended March 31, 2018 of $19,137,266 compared to Fiscal Year Ended March 31, 2017 audited revenues of $355,959; a year-over-year increase of 5276%.\n “Although the Company experienced tremendous growth for its Fiscal Year 2018, we strongly believe that CBD is still in its infancy stage, and we are just beginning to understand its benefits for the human body,” said CEO of Isodiol, Marcos Agramont.  “Isodiol has made significant strategic acquisitions over the last 12 months that are just now beginning to bear fruit, and the Company is well positioned as a global leader in the manufacturing, distribution, and full commercialization of hemp-derived CBD products.” Isodiol believes it has a strong balance sheet with $24,069,692 in cash and acquisition deposits, which are intended to facilitate continued growth throughout Fiscal Year 2019.  With positive changes in regulation that have affected the legality of hemp and CBD around the globe, the Company is expanding its worldwide sales force with the intention of capitalizing on the untapped market for API sales and Finished Pharmaceutical Products. The Company incurred significant acquisition advisory and consulting costs during Fiscal Year 2018 that the Company deemed necessary to accomplish the following transactions: Iso International LLC Isodiol is the industry leader in hemp-derived phytocannabinoids. It produces 99%+ pure, natural nutraceutical- and pharmaceutical-grade bulk ingredients and nutraceutical consumer products for global distribution and direct-to-consumer sale. Pot-O-Coffee The Pot-O-Coffee product line consists of two coffee variants for cannabis infusion—one infused with cannabis plant-extracted tetrahydrocannabinol (THC) oil, while the other is infused with non-psychotropic cannabidiol (CBD) derived from agricultural b...